

Crigler-Najjar syndrome

Description

Crigler-Najjar syndrome is a severe condition characterized by high levels of a toxic substance called bilirubin in the blood (hyperbilirubinemia). Bilirubin is produced when red blood cells are broken down. This substance is removed from the body only after it undergoes a chemical reaction in the liver, which converts the toxic form of bilirubin (called unconjugated bilirubin) to a nontoxic form called conjugated bilirubin. People with Crigler-Najjar syndrome have a buildup of unconjugated bilirubin in their blood (unconjugated hyperbilirubinemia).

Bilirubin has an orange-yellow tint, and hyperbilirubinemia causes yellowing of the skin and whites of the eyes (jaundice). In Crigler-Najjar syndrome, jaundice is apparent at birth or in infancy. Severe unconjugated hyperbilirubinemia can lead to a condition called kernicterus, which is a form of brain damage caused by the accumulation of unconjugated bilirubin in the brain and nerve tissues. Babies with kernicterus are often extremely tired (lethargic) and may have weak muscle tone (hypotonia). These babies may experience episodes of increased muscle tone (hypertonia) and arching of their backs. Kernicterus can lead to other neurological problems, including involuntary writhing movements of the body (choreoathetosis), hearing problems, or intellectual disability.

Crigler-Najjar syndrome is divided into two types. Type 1 (CN1) is very severe, and affected individuals can die in childhood due to kernicterus, although with proper treatment, they may survive longer. Type 2 (CN2) is less severe. People with CN2 are less likely to develop kernicterus, and most affected individuals survive into adulthood.

Frequency

Crigler-Najjar syndrome is estimated to affect fewer than 1 in 1 million newborns worldwide.

Causes

Mutations in the *UGT1A1* gene cause Crigler-Najjar syndrome. This gene provides instructions for making the bilirubin uridine diphosphate glucuronosyl transferase (bilirubin-UGT) enzyme, which is found primarily in liver cells and is necessary for the removal of bilirubin from the body.

The bilirubin-UGT enzyme performs a chemical reaction called glucuronidation. During this reaction, the enzyme transfers a compound called glucuronic acid to unconjugated bilirubin, converting it to conjugated bilirubin. Glucuronidation makes bilirubin dissolvable in water so that it can be removed from the body.

Mutations in the *UGT1A1* gene that cause Crigler-Najjar syndrome result in reduced or absent function of the bilirubin-UGT enzyme. People with CN1 have no enzyme function, while people with CN2 have less than 20 percent of normal function. The loss of bilirubin-UGT function decreases glucuronidation of unconjugated bilirubin. This toxic substance then builds up in the body, causing unconjugated hyperbilirubinemia and jaundice.

[Learn more about the gene associated with Crigler-Najjar syndrome](#)

- *UGT1A1*

Inheritance

Crigler-Najjar syndrome is inherited in an autosomal recessive pattern, which means both copies of the *UGT1A1* gene in each cell have mutations. A less severe condition called Gilbert syndrome can occur when one copy of the *UGT1A1* gene has a mutation.

Other Names for This Condition

- Crigler Najjar syndrome
- Familial nonhemolytic unconjugated hyperbilirubinemia
- Hereditary unconjugated hyperbilirubinemia

Additional Information & Resources

Genetic Testing Information

- Genetic Testing Registry: Crigler-Najjar syndrome, type II (<https://www.ncbi.nlm.nih.gov/gtr/conditions/C2931132/>)
- Genetic Testing Registry: Crigler-Najjar syndrome type 1 (<https://www.ncbi.nlm.nih.gov/gtr/conditions/C0010324/>)

Genetic and Rare Diseases Information Center

- Crigler-Najjar syndrome type 1 (<https://rarediseases.info.nih.gov/diseases/47/index>)
- Crigler-Najjar syndrome type 2 (<https://rarediseases.info.nih.gov/diseases/8683/index>)

Patient Support and Advocacy Resources

- National Organization for Rare Disorders (NORD) (<https://rarediseases.org/>)

Clinical Trials

- ClinicalTrials.gov ([https://clinicaltrials.gov/search?cond=%22Crigler-Najjar syndrome%22](https://clinicaltrials.gov/search?cond=%22Crigler-Najjar+syndrome%22))

Catalog of Genes and Diseases from OMIM

- CRIGLER-NAJJAR SYNDROME, TYPE I (<https://omim.org/entry/218800>)
- CRIGLER-NAJJAR SYNDROME, TYPE II (<https://omim.org/entry/606785>)

Scientific Articles on PubMed

- PubMed (<https://pubmed.ncbi.nlm.nih.gov/?term=%28Crigler-Najjar+Syndrome%5BMAJR%5D%29+AND+%28Crigler-Najjar+syndrome%5BTIAB%5D%29+AND+english%5Bla%5D+AND+human%5Bmh%5D+AND+%22last+1800+days%22%5Bdp%5D%29>)

References

- Bosma PJ. Inherited disorders of bilirubin metabolism. J Hepatol. 2003Jan;38(1):107-17. doi: 10.1016/s0168-8278(02)00359-8. No abstract available. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/12480568>)
- Servedio V, d'Amico M, Maiorano N, Minuti B, Torricelli F, Ronchi F, Zancan L, Perrotta S, Vajro P, Boschetto L, Iolascon A. Spectrum of UGT1A1 mutations in Crigler-Najjar (CN) syndrome patients: identification of twelve novel alleles and genotype-phenotype correlation. Hum Mutat. 2005 Mar;25(3):325. doi:10.1002/humu.9322. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/15712364>)
- Sneitz N, Bakker CT, de Knecht RJ, Halley DJ, Finel M, Bosma PJ. Crigler-Najjar syndrome in The Netherlands: identification of four novel UGT1A1 alleles, genotype-phenotype correlation, and functional analysis of 10 missense mutants. Hum Mutat. 2010 Jan;31(1):52-9. doi: 10.1002/humu.21133. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/19830808>)
- Udomuksorn W, Elliot DJ, Lewis BC, Mackenzie PI, Yoovathaworn K, Miners JO. Influence of mutations associated with Gilbert and Crigler-Najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 1A substrates. Pharmacogenet Genomics. 2007Dec;17(12):1017-29. doi: 10.1097/FPC.0b013e328256b1b6. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/18004206>)

Last updated February 1, 2012